NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

US Senate committee sets hearing on China's WuXi AppTec, BGI bill

Published 02/26/2024, 05:58 PM
Updated 02/26/2024, 08:06 PM
© Reuters. The logo of Chinese drug research and development group WuXi AppTec is displayed alongside its company website, in this illustration picture taken February 5, 2024. REUTERS/Florence Lo/Illustration

By Karen Freifeld

(Reuters) -A U.S. Senate committee said on Monday it will hold a hearing on March 6 on a bill that would prohibit federal agencies from contracting with China's BGI, WuXi AppTec and other biotechnology companies of concern.

The bill would also stop the government from entering into contracts with companies that use the Chinese companies' equipment or services. News of the Senate bill, and similar legislation in the House, has sent shares of WuXi AppTec tumbling in recent weeks on fears it would hurt the company's large U.S. business.

The legislation is intended to prevent foreign adversaries from stealing American genetic data and personal health information, according to a statement on the U.S. Senate Homeland Security and Governmental Affairs Committee website.

The committee's hearing is a procedural step, also called a mark-up, to discuss next steps on the bill, which was sponsored by Democratic Senator Gary Peters.

A House bill introduced by Republican congressman Mike Gallagher, chair of the House select committee on China, accuses the companies of aiding Beijing's military.

WuXi AppTec has denied ties to China's military and said its business does not pose national security risks to any country.

WuXI AppTec operates in more than a half-dozen U.S. states including Pennsylvania, California and Delaware, where a subsidiary is investing some $500 million in a manufacturing facility. Two-thirds of its revenue came from the U.S. market in the first nine months of 2023, according to an investor

The company, which also has sites in Europe and China, offers a wide range of services to the pharmaceutical and healthcare industry.

BGI Group has said that statements alleging it is controlled by the Chinese government or military are false. It has said it supports protecting personal data, but that the legislation will not accomplish that goal because it "will effectively drive BGI from the U.S. market."

Earlier this month a bipartisan group of lawmakers told top Biden administration officials that the U.S. should review WuXi AppTec for sanctions.

© Reuters. The logo of Chinese drug research and development group WuXi AppTec is displayed alongside its company website, in this illustration picture taken February 5, 2024. REUTERS/Florence Lo/Illustration

The lawmakers told Treasury Secretary Janet Yellen, Defense Secretary Lloyd Austin and Commerce Secretary Gina Raimondo that the company's links to China's Communist Party and military threatened U.S. national security.

WuXi AppTec shares have fallen 36% in the last month.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.